Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRFR20250602009
- Term of Validity
- 3 June 2025 - 3 June 2026
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French SME seeks a consortium led by a biotech SME with a Phase I/II clinical trial project in a motricity-affecting disease to join a Horizon Europe project (HORIZON-HLTH-2025-01-TOOL-05) aimed at boosting the translation of biotech research into innovative health therapies.
- Full Description
-
A French SME is offering a real-world digital endpoint platform based on high-precision wearable sensors, to accelerate medical progress on diseases affecting motor function.
This solution provides the first regulatory-qualified digital endpoint : "SV95C", a measure of the patient's maximal gait speed.
It also provides a number of endpoints assessing lower-limb and upper-limb motricity and has supported dozens of clinical trials.
In relevant diseases, the higher sensitivity of the SME's digital endpoints, compared with traditional controlled-environment clinical outcomes, can allow the measure of a therapy's efficacy to reach statistical significance with a smaller number of patients and shorter follow-up durations, thus accelerating the clinical development of the therapy.
The project call "HORIZON-HLTH-2025-01-TOOL-05 : boosting the translation of biotech research into innovative health therapies" aims to speed up the development of innovative biotechnology-based therapies by supporting Phase I/II clinical trials.
The SME's solution would therefore fit perfectly in the scope of this project call. It is seeking to join a consortium led by a biotech SME with a Phase I/II clinical trial project in a motricity-affecting disease. - Advantages and Innovations
- Real-world digital endpoint platform based on high-precision wearable sensors, with a proven track record of accelerating medical progress in diseases affecting motor function.Real-world digital endpoint platform based on high-precision wearable sensors, with a proven track record of accelerating medical progress in diseases affecting motor function.
- Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- The partner should be a biotech SME with a Phase I, II or I/II clinical trial project in a motricity-affecting disease, willing to use a digital endpoint platform in its trial and to lead a consortium applying to the project call "HORIZON-HLTH-2025-01-TOOL-05".
- Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Horizon Europe
- Call title and identifier
-
HORIZON-HLTH-2025-01-TOOL-05
- Submission and evaluation scheme
-
HORIZON-RIA HORIZON Research and Innovation Actions
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Web link to the call
- https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportuni…
- Project title and acronym
-
Developing and using new tools, technologies and digital solutions for a healthy society
- Horizon Europe
Dissemination
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Sector Groups Involved
- Health
- Targeted countries
- All countries